Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
about
Current Trends of Renal Impairment in Multiple MyelomaAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Bortezomib in patients with renal impairment.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaBortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report.Renal failure in multiple myeloma: a medical emergency.Management of hematological malignancies in patients affected by renal failure.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A retrospective study from a single center.Shoulder pad sign and asymptomatic hypercalcemia in a patient with end-stage kidney disease.Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.Renal failure caused by plasma cell infiltration in multiple myeloma.Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
P2860
Q26740444-C36D60EC-C20C-4AD5-9496-220D786CB32AQ30595175-8560F332-67F9-4A1E-8A60-BE33726F78DBQ33396250-46477B85-C683-4B82-B5C6-502E0C5D9EC8Q33407105-4EB30767-EE38-4093-A170-326A2624E754Q33408056-8A7EF003-60E6-41E3-8133-B09F3B10DA37Q36544872-72FBC0F5-AA94-4037-AA9D-7BD5367B4B6AQ36686965-CA1A9019-E47E-45CC-90F1-AC3343F7CF5BQ37204229-5570C199-6773-41CA-B227-032F75ECA5DFQ37845643-6054C103-BA82-4609-840E-E9C4272CD4F0Q37854710-1C53A8E3-8C76-45D1-B342-662844F621FAQ37903590-B4BB29AA-59BC-4A20-AD65-A27F5528B029Q37978343-74774820-689A-4AFA-8F30-8916E8551175Q37986358-262A3AEF-B021-4B31-9A25-A24C01B6F34BQ38109235-35227DFF-D54D-4861-B002-D46590EDBC54Q38555091-73B849AB-472E-4D12-98CD-5A7912874B58Q38802354-881C13B9-063E-4C7C-8468-C7439D39B75DQ38900024-3C6281B2-43CF-4677-9EE6-5E76C72E6559Q38959138-E198D4D9-C67F-47CA-A2F4-9127F6BF2D53Q40626336-7DB4AA98-FA93-4FDE-A1A1-BE504E52E374Q40718791-CF2A319E-7C68-4788-9C0F-85112CC577D8Q40774098-A498F195-3722-48AB-BD9F-CBCFCC2538E3Q43187527-47797B96-70AB-43A3-9978-50312F0ADF8BQ50055765-5B6AE41B-8628-4D97-9470-C9A7FEE94F63Q50089740-2E7EDA6E-7C36-4051-B3EC-1CBDAD429161Q51487130-32DE320E-D573-4FDD-9F52-E2D6F7D7F5D6Q53179212-9F33974A-CFA5-46AC-BE83-354575EA2173
P2860
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@en
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@nl
type
label
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@en
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@nl
prefLabel
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@en
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@nl
P2093
P50
P1476
Safety and efficacy of bortezo ...... talian Myeloma Network GIMEMA.
@en
P2093
Antonio F Casulli
Donato Mannina
Eugenio Piro
Fortunato Morabito
Giuseppe Mele
Graziella Pinotti
Lucio Catalano
Maria T Petrucci
Mario Boccadoro
Massimo Gentile
P304
P356
10.1111/J.1600-0609.2009.01385.X
P577
2009-11-23T00:00:00Z